StockNews.AI
CAPR
StockNews.AI
39 days

INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC

1. Capricor received a Complete Response Letter from the FDA on July 11, 2025. 2. The stock price of Capricor dropped following the FDA's response. 3. Holzer & Holzer, LLC is investigating Capricor for potential securities law compliance issues. 4. Investors are encouraged to seek legal recourse due to stock losses. 5. Holzer & Holzer has a history of representing investors in securities litigation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The receipt of a CRL typically indicates setbacks in drug approval processes, negatively impacting stock values. Historical cases like ARNA Pharmaceuticals demonstrated significant price drops following adverse regulatory news.

How important is it?

The ongoing investigation and FDA challenge severely impact shareholder confidence and stock performance. Such legal and regulatory scrutiny can heighten volatility and affect investor sentiment.

Why Short Term?

The immediate effect of regulatory news, particularly CRLs, is often swift; investors typically react within days. Future impacts depend on response strategies and subsequent FDA interactions.

Related Companies

ARNASPPISAVAVKTXCRMD
ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding its Biologics License Application (“BLA”) for Deramiocel. Following this news, the price of the Company’s stock dropped.  If you purchased Capricor stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/capricor/ to discuss your legal rights.   Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. CONTACT:Corey Holzer, Esq.(888) 508-6832 (toll-free) cholzer@holzerlaw.com

Related News